Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 16/20 | 0.45 |
| ▸ | CSF1R | P07333 | 15/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194484 | 1.00 | FGFR4 (0.46) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL23301942 | 1.00 | FGFR4 (0.46) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL30194429 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL24949938 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL24949955 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL30194562 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL23301724 | 0.95 | EGFR (0.42) | FGFR4EGFRCSF1RUSP30 | |
| SCHEMBL29894192 | 0.95 | EGFR (0.42) | FGFR4EGFRCSF1RUSP30 | |
| SCHEMBL30194652 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA | |
| SCHEMBL30194639 | 0.95 | FGFR4 (0.51) | FGFR4EGFRCSF1RUSP30PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-30 | — | — | US | disclosed |
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-4051677-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 | Cancer Research Technology Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | SIK2, SIK1, SIK3 | FGFR4 991/4885EGFR 1693/4885CSF1R 1398/4885 |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | SIK2, SIK1, SIK3 | FGFR4 1045/4885EGFR 1167/4885CSF1R 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.